ERNEXA THERAPEUTICS INC.
Profile
Company Names
ERNEXA THERAPEUTICS INC.
ETERNA THERAPEUTICS INC.
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NTN BUZZTIME INC
Addresses
1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA 02141
10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO, CA 92121
140 58TH STREET, BUILDING A, SUITE 2100, BROOKLYN, NY 11220
2231 RUTHERFORD RD. #200, CARLSBAD, CA 92008
5966 LA PLACE COURT, SUITE 100, CARLSBAD, CA 92008
Phone Numbers
(617) 798-6700
(212) 582-1199
(760) 476-3543
760-438-7400
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY, OTHER, TELECOMMUNICATIONS
Year Incorporated:
> 5 years ago
State Incorporated:
DE
Total Amount Raised:
$49,253,619.00
Number of Funding Rounds:
8
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
8
2025-03-31
$7,249,999.00
$7,249,999.00
$0.00
Equity
7
2024-09-24
$1,137,746.00
$1,137,746.00
$0.00
Equity
6
2023-12-15
$7,788,000.00
$9,193,000.00
$1,405,000.00
Equity, Debt
5
2023-07-14
$8,715,000.00
$8,715,000.00
$0.00
Equity, Debt
4
2022-12-02
$7,712,874.00
$7,712,874.00
$0.00
Equity
3
2022-03-09
$12,000,000.00
$12,000,000.00
$0.00
Equity
2
2013-11-12
$2,400,000.00
$3,840,000.00
$1,440,000.00
Equity
1
2009-05-11
$2,250,000.00
$2,250,000.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
MATTHEW
ANGEL
EXECUTIVE OFFICER, DIRECTOR
JAMES
BRISTOL
DIRECTOR
CHARLES
CHERINGTON
DIRECTOR
INTERVALE CAPITAL FUND II, L.P.
| INTERVALE CAPITAL FUND II-A, L.P.
| INTERVALE CAPITAL FUND III, L.P.
| INTERVALE/TRF INVESTOR LLC
| ARA FUND I, LP
| BROOKLYN IMMUNOTHERAPEUTICS, INC.
| UTILITY GLOBAL, INC.
| SQUARE ROBOT, INC.
| ARA LINCOLN CO-INVEST, LP
| ETERNA THERAPEUTICS INC.
| ARA DIVERT HOLDCO, INC.
| ARA INFRASTRUCTURE FUND I-A, SCSP
| ARA FUND III-A, SCSP
| ARA FUND III, LP
| ARA INFRASTRUCTURE FUND I, LP
| ARA LINCOLN CO-INVEST-A, LP
SANDRA
GURROLA
EXECUTIVE OFFICER
ANDREW
JACKSON
EXECUTIVE OFFICER
DENNIS
LANGER
DIRECTOR
DICERNA PHARMACEUTICALS INC
| LIGHT SCIENCES ONCOLOGY INC
| INNOCOLL HOLDINGS, INC.
| SANCILIO + COMPANY, INC.
| ALZHEON, INC.
| SANCILIO PHARMACEUTICALS COMPANY, INC.
| MYRIAD GENETICS INC
| QUOIN PHARMACEUTICALS, INC.
| NEXEOS DIAGNOSTICS, INC.
| BROOKLYN IMMUNOTHERAPEUTICS, INC.
| QUOIN PHARMACEUTICALS, LTD.
| AVICENNA BIOSCIENCES, INC.
| EMPIRICO INC.
ERICH
MOHR
DIRECTOR
NICHOLAS
J.
SINGER
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
$1 - $1,000,000
Equity
2025-03-31
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
$1 - $1,000,000
Equity
2024-09-24
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
NO REVENUES
Equity, Debt
2023-12-15
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity, Debt
2023-07-14
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity, Debt
2023-07-14
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2022-12-02
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2022-03-09
D
OTHER
TELEVISION BROADCASTING STATIONS [4833]
$5,000,001 - $25,000,000
Equity
2013-11-12
D
TELECOMMUNICATIONS
TELEVISION BROADCASTING STATIONS [4833]
$25,000,001 - $100,000,000
Equity
2009-05-11

